Literature DB >> 32635782

Interferons: role in cancer therapy.

Mohadeseh Haji Abdolvahab1, Behrad Darvishi1, Mohammad Zarei2,3, Keivan Majidzadeh-A1, Leila Farahmand1.   

Abstract

Interferons (IFNs) are a group of signaling cytokines, secreted by host cells to induce protection against various disorders. IFNs can directly impact on tumor cells or indirectly induce the immune system to protect host cells. The expression levels of IFNs and its functions of are excellently modulated in a way to protect host cells from probable toxicities caused by extreme responses. The efficacy of anticancer therapies is correlated to IFNs signaling. Although IFN signaling is involved in induction of antitumor responses, chronic stimulation of the IFN signaling pathway can induce resistance to various antineoplasm therapies. Hence, IFNs are expressed by both cancer and immune cells, and modulate their biological function. Understanding this mechanism of action might be a key target of combination therapies.

Entities:  

Keywords:  cancer; cancer therapy; immunotherapy; interferons; tumor

Year:  2020        PMID: 32635782     DOI: 10.2217/imt-2019-0217

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  6 in total

1.  Type I IFN stimulates IFI16-mediated aromatase expression in adipocytes that promotes E2-dependent growth of ER-positive breast cancer.

Authors:  Na-Lee Ka; Ga Young Lim; Seung-Su Kim; Sewon Hwang; Juhyeong Han; Yun-Hee Lee; Mi-Ock Lee
Journal:  Cell Mol Life Sci       Date:  2022-05-20       Impact factor: 9.207

2.  Interferon Beta Activity Is Modulated via Binding of Specific S100 Proteins.

Authors:  Alexey S Kazakov; Alexander D Sofin; Nadezhda V Avkhacheva; Alexander I Denesyuk; Evgenia I Deryusheva; Victoria A Rastrygina; Andrey S Sokolov; Maria E Permyakova; Ekaterina A Litus; Vladimir N Uversky; Eugene A Permyakov; Sergei E Permyakov
Journal:  Int J Mol Sci       Date:  2020-12-13       Impact factor: 5.923

3.  Interferon-β Activity Is Affected by S100B Protein.

Authors:  Alexey S Kazakov; Alexander D Sofin; Nadezhda V Avkhacheva; Evgenia I Deryusheva; Victoria A Rastrygina; Maria E Permyakova; Vladimir N Uversky; Eugene A Permyakov; Sergei E Permyakov
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

4.  Oncogenic Mutation BRAF V600E Changes Phenotypic Behavior of THLE-2 Liver Cells through Alteration of Gene Expression.

Authors:  Magdalena Śmiech; Paweł Leszczyński; Christopher Wardell; Piotr Poznański; Mariusz Pierzchała; Hiroaki Taniguchi
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

Review 5.  Ulcerated Cutaneous Melanoma: A Review of the Clinical, Histologic, and Molecular Features Associated with a Clinically Aggressive Histologic Phenotype.

Authors:  Zoe Barricklow; Mallory J DiVincenzo; Colin D Angell; William E Carson
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-30

6.  Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer.

Authors:  Dilraj Kaur; Chakit Arora; Gajendra Pal Singh Raghava
Journal:  Mol Diagn Ther       Date:  2021-06-22       Impact factor: 4.074

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.